November 1, 2016
USFDA opens door to $30M market for India’s Strides Shasun’s HIV-1 infection tablets
India’s Strides Shasun Limited has received approval from the USFDA for Abacavir Tablets
Pharmaceuticals, Biotechnology and Life Sciences
Category: North America
October 31, 2016
Exclusive: EpiPen price hikes add millions to Pentagon costs
Mylan NV’s price hikes on EpiPens have added millions to U.S. Department of Defense spending…
October 31, 2016
FDA gives de novo approval for BD’s vaginitis detector
BD has gotten FDA market authorization for a first-of-its-kind molecular test…
October 31, 2016
HeartWare recalls HVAD controller used in patients with heart condition
HeartWare is recalling the HVAD controller due to a loose power connector which may cause …
October 31, 2016
Allergan’s chronic dry eye drops will make patients shed more tears
Allergan has received approval from the FDA for Restasis, treatment to help patients with a type of Chronic Dry Eye …
October 27, 2016
Newly approved drugs push Lilly’s revenues 5% up, but net income went 3% down
The world’s leading drugmaker Eli Lilly saw a decline in net income for the third…
October 25, 2016
Bangladesh’s Beximco gets its second US FDA product approval
Bangladesh-based Beximco, the largest country’s pharmaceutcals exporter, has received its second US FDA …
October 20, 2016
FDA approves Lilly’s Lartruv for soft tissue sarcoma treatment
Eli Lilly and Company announced that FDA has granted approval of LARTRUV (olaratumab injection, 10 mg/mL), in combination with doxorubicin, for the treatment of adults with soft tissue sarcoma (STS) with a histologic subtype for which an anthracycline-containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or surgery.
October 19, 2016
Pfizer’s Inflectra (Chron’s disease) soon available in US
Pfizer will begin shipment of INFLECTRA (infliximab-dyyb) for injection, a biosimilar of REMICADE 1 (infliximab) to wholesalers in the United States (U.S.) in late November 2016.
October 19, 2016
GW Pharmaceutical cancels trading shares on AIM on December 2, 1016, continues trading on NASDAQ
GW Pharmaceuticals plc has announced leaving AIM and canceling trading in London, to continue trading only on NASDAQ.